VMAT2 Inhibitors: Valbenazine (Ingrezza) and Deutetrabenazine (Austedo)

from PsychRounds: The Psychiatry Podcast · host Dr. Tanner Hewitt, Dr. Larry Wang and Dr. Bradley Miller

Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo). References: https://pubmed.ncbi.nlm.nih.gov/41626799/https://www.ncbi.nlm.nih.gov/books/NBK548187/https://pubmed.ncbi.nlm.nih.gov/41626799/

Episode metadata supplied by the publisher feed · Published Mar 21, 2026

Embed this episode

Attribution link and audio player

Ready to play

VMAT2 Inhibitors: Valbenazine (Ingrezza) and Deutetrabenazine (Austedo)

0:00 17:19

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of PsychRounds: The Psychiatry Podcast?

This episode is 17 minutes long.

When was this PsychRounds: The Psychiatry Podcast episode published?

This episode was published on March 21, 2026.

Can I download this PsychRounds: The Psychiatry Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!